References
- Henry J, Smeyne R, Jang H, et al. Parkinsonism and neurological
manifestations of influenza throughout the 20th and 21st centuries.
Parkinsonism Relat Disord 2010;16:566–571.
- Pinto, L. H., and R. A. Lamb. Understanding the mechanism of action of
the anti-influenza virus drug amantadine. Trends Microbiol.
1995;3:271.
- Roberto Cilia, Salvatore Bonvegna, Giulia Straccia, et al. Effects of
COVID‐19 on Parkinson’s disease clinical features: a community‐based
case‐control study. Mov Disord. 2020; 10.1002/mds.28170. doi:
10.1002/mds.28170 [Epub ahead of print] PMCID: PMC7280741
- Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T.,
Zhang, X., Chen, H., Yu, H., et al. (2020c). Clinical and
immunological features of severe and moderate coronavirus disease
2019. J Clin Invest. 2020;130(5):2620-2629.
https://doi.org/10.1172/JCI137244.
- Nie, S., Zhao, X., Zhao, K., Zhang, Z., Zhang, Z., and Zhang, Z.
(2020b). Metabolic disturbances and inflammatory dysfunction predict
severity of coronavirus disease 2019 (COVID-19): a retrospective
study. medRxiv. https://doi.org/10.1101/2020.03.24.20042283.
- Philip W. Tipton, Zbigniew K. Wszolek. What can Parkinson’s disease
teach us about COVID-19? Neurologia i Neurochirurgia Polska Polish
Journal of Neurology and Neurosurgery 202054;2:204–206.